News - Sandoz, Astellas Pharma

Filter

Current filters:

SandozAstellas Pharma

Popular Filters

1 to 25 of 184 results

Promising emerging agents for triple negative breast cancer

08-04-2014

Due to the heterogeneity of triple negative breast cancer, the most promising emerging agents in development…

Astellas PharmaBiotechnologyMarkets & MarketingMedivationniraparibOncologyTesaroXtandi

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

07-04-2014

Uptake of biosimilars in Europe has increased as a result of member states’ policies, according to…

BiosimilarsEuropeFilgrastimInterviewsMarkets & MarketingRegulationSandoz

Astellas files for wider use of prostate cancer drug Xtandi in Europe

03-04-2014

Japanese drug major Astellas Pharma has submitted a variation to amend the Marketing Authorization Application…

Astellas PharmaEuropeMedivationOncologyPharmaceuticalRegulationXtandi

Astellas’ Xtandi cleared in Japan for prostate cancer treatment

24-03-2014

Japanese drug major Astellas Pharma has obtained the marketing approval in Japan of its oral androgen…

Asia-PacificAstellas PharmaJapanMedivationOncologyPharmaceuticalRegulationXtandi

Astellas and Daiichi Sankyo share 400,000 compounds in research agreement

Astellas and Daiichi Sankyo share 400,000 compounds in research agreement

19-03-2014

Japanese drug majors Astellas Pharma and Daiichi Sankyo will form a compound library sharing partnership…

Astellas PharmaDaiichi SankyoJapanLicensingPharmaceuticalResearch

Astellas and Medivation file sNDA for new Xtandi indication

Astellas and Medivation file sNDA for new Xtandi indication

18-03-2014

Japanese drug major Astellas Pharma and US partner Medivation have filed a supplemental New Drug Application…

Astellas PharmaMedivationNorth AmericaOncologyPharmaceuticalRegulationUSAXtandi

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

07-03-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has decided to award immunosuppressant drug…

Asia-PacificGenericsImmunologicalsMarkets & MarketingNew ZealandNovartisPricingSandozTacrolimus Sandoz

Cumberland Pharma acquires Vaprisol from Astellas

03-03-2014

USA-based Cumberland Pharmaceuticals says it has acquired from the US subsidiary of Japan’s Astellas…

Astellas PharmaCumberland PharmaceuticalsHematologyLicensingNorth AmericaPharmaceuticalUSAVaprisol

Astellas amends license deal for isavuconazole with Basilea

01-03-2014

Japanese drug major Astellas Pharma has amended the license, co-development and co-promotion agreement…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCanadaisavuconazoleLicensingNorth AmericaPharmaceuticalUSA

IQWiG now finds “major” benefit for Xtandi

24-02-2014

In an early benefit assessment under Germany’s Act on the Reform of the Market for Medicinal Products…

Astellas PharmaGermanyMedivationNorthern EuropeOncologyPharmaceuticalPricingRegulationXtandi

AVEO and Astellas finally terminate tivozanib collaboration

14-02-2014

US biotech firm AVEO Oncology and Japanese drug major Astellas Pharma are to end their worldwide collaboration…

Astellas PharmaAVEO OncologyBiotechnologyLicensingOncologytivozanib

Five big pharma firms named as high performers in annual biopharmaceutical report

Five big pharma firms named as high performers in annual biopharmaceutical report

12-02-2014

Entry in emerging markets and expedient product launches are still driving the pharma market, according…

AmgenAstellas PharmaBristol-Myers SquibbFinancialMarkets & MarketingNovo NordiskPharmaceuticalResearchRoche

Medivation and Astellas announce final results of Phase III enzalutamide trial in prostate cancer

Medivation and Astellas announce final results of Phase III enzalutamide trial in prostate cancer

29-01-2014

Medivation and Japanese drug major Astellas Pharma have announced final results on the primary and secondary…

Astellas PharmaenzalutamideMedivationOncologyPharmaceuticalResearchUSAXtandi

Latest guidance from UK’s NICE on Xtandi disappoints Astellas

Latest guidance from UK’s NICE on Xtandi disappoints Astellas

28-01-2014

UK drugs watchdog the National Institute of Health and Care Excellence (NICE) has issued new draft guidance…

Astellas PharmaEuropeOncologyPharmaceuticalPricingRegulationUKXtandi

Astellas gains Japanese clearance for diabetes drug Suglat

Astellas gains Japanese clearance for diabetes drug Suglat

20-01-2014

Japanese drug major Astellas Pharma has obtained the marketing approval of selective SGLT2 inhibitor…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalMerck & CoPharmaceuticalRegulationSuglat

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

15-01-2014

Japanese drug major Astellas Pharma and partner UMN Pharma have announced promising summary results for…

Asia-PacificASP7374Astellas PharmaGastro-intestinalsIrribowMarkets & MarketingPharmaceuticalResearchUMN PharmaVaccines

Sandoz to commercialize Taiwan Liposome’s antifungal

Sandoz to commercialize Taiwan Liposome’s antifungal

19-12-2013

Taipei-based biopharmaceutical company Taiwan Liposome Company has entered into a collaboration agreement…

Amphotericin BAntibiotics and Infectious diseasesAsia-PacificGenericsLicensingNovartisSandozTaiwan Liposome

Sandoz launches Phase III trial of biosimilars of AbbVie’s Humira

Sandoz launches Phase III trial of biosimilars of AbbVie’s Humira

19-12-2013

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), has initiated a Phase III clinical…

AbbVieBiosimilarsHumiraImmunologicalsNorthern EuropeResearchSandoz

Sandoz receives Danish approval for AirFluSal Forspiro inhaler

Sandoz receives Danish approval for AirFluSal Forspiro inhaler

19-12-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has received Danish marketing authorization…

DenmarkPharmaceuticalRegulationRespiratory and PulmonarySandozVectura

Apricus expands Vitaros deal with Novartis unit

Apricus expands Vitaros deal with Novartis unit

16-12-2013

USA-based Apricus Biosciences has expanded its exclusive license agreement with Hexal AG, an affiliate…

Apricus BioscienceEuropeLicensingMen's HealthNovartisPharmaceuticalSandozVitaros

More disappointment for AVEO’s tivozanib in colorectal cancer

More disappointment for AVEO’s tivozanib in colorectal cancer

14-12-2013

There was yet another setback for US biotech firm AVEO Oncology on Friday), when the company announced…

Astellas PharmaAVEO OncologyBiotechnologyOncologyResearch

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

11-12-2013

The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care…

EuropefentanylFinancialJohnson & JohnsonNeurologicalNovartisPatentsPharmaceuticalSandoz

1 to 25 of 184 results

Back to top